# A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

> **NCT06362369** · PHASE1,PHASE2 · RECRUITING · sponsor: **7 Hills Pharma, LLC** · enrollment: 126 (estimated)

## Conditions studied

- Advanced Cancer
- Advanced Solid Tumor
- Melanoma
- Metastasis
- Pleural Mesothelioma
- Renal Cell Carcinoma
- MSI-High
- Mismatch Repair Deficiency
- Colorectal Cancer
- Hepatocellular Carcinoma
- Hepatocellular Cancer
- Renal Cell Cancer
- Kidney Cancer
- Skin Cancer
- Non Small Cell Lung Cancer
- NSCLC
- Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
- ALK Genomic Tumor Aberrations

## Interventions

- **DRUG:** Alintegimod
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT06362369
- **Lead sponsor:** 7 Hills Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-23
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06362369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06362369, "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06362369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*